论文部分内容阅读
目的:探讨奥曲肽治疗肠梗阻的疗效及并发症。方法:48例肠梗阻患者分为奥曲肽组(25例)和对照组(23例),两组间年龄、性别及肠梗阻的病因比较无显著性差异(P>0.05)。奥曲肽组25例采用奥曲肽(善宁)0.1mg H q 6 h或q 8 h,连用3～14 d,同时按常规治疗禁食、胃肠减压、补液及纠正水电解质酸碱失衡;23例对照组按常规治疗禁食、胃肠减压、补液及纠正水电解质酸碱失衡。结果:奥曲肽组的治愈率为76％,对照组的治愈率为52％,两组比较无显著性差异(P>0.05)。但奥曲肽组的症状缓解率为80％,平均肛门排气时间为3.4±1.4 d,平均住院时间8.5±2.6d,副作用发生率为12％;对照组症状缓解率为26％,平均肛门排气时间为6.8±2.4d、平均住院时间10.7±2.3 d,副作用发生率为43％。两组比较均有显著性差异(P<0.05～0.001)。结论:奥曲肽在治疗肠梗阻上是一种新的、安全及有效药物。
Objective: To investigate the efficacy and complications of octreotide in treating intestinal obstruction. Methods: 48 patients with intestinal obstruction were divided into octreotide group (n = 25) and control group (n = 23). There was no significant difference in age, sex and intestinal obstruction between the two groups (P> 0.05). Octreotide group 25 patients with octreotide 0.1mg H q 6 h or q 8 h, once every 3 to 14 d, while conventional treatment of fasting, gastrointestinal decompression, rehydration and correct water and electrolyte acid-base imbalance; 23 cases Control group according to conventional treatment of fasting, gastrointestinal decompression, rehydration and correct water and electrolyte acid-base imbalance. Results: The cure rate of octreotide group was 76%, while that of control group was 52%. There was no significant difference between the two groups (P> 0.05). However, the symptom relief rate of octreotide group was 80%, the average anal exhaust time was 3.4 ± 1.4 days, the average length of hospital stay was 8.5 ± 2.6 days, and the incidence of side effects was 12%. In the control group, the symptom relief rate was 26% The time was 6.8 ± 2.4d, the average length of stay was 10.7 ± 2.3 days and the incidence of side effects was 43%. There was significant difference between the two groups (P <0.05 ~ 0.001). Conclusion: Octreotide is a new, safe and effective drug in the treatment of intestinal obstruction.